A high-level overview of Galmed Pharmaceuticals Ltd. (GLMD) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and

Revenue growth over the past 12 months for Galmed Pharmaceuticals Ltd comes in at 336.4%, a number that bests 97.89% of the US stocks we're tracking. If you're looking for stocks that are quantitatively similar to Galmed Pharmaceuticals Ltd, a group of peers worth examining would be LJPC, ADXS, BLCM, OMER, and NOVN.

It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. Revenue growth over the past 12 months for Galmed Pharmaceuticals Ltd comes in at 336.4%, a number that bests 97.89% of the US stocks we're tracking. If you're looking for stocks that are quantitatively similar to Galmed Pharmaceuticals Ltd, a group of peers worth examining would be LJPC, ADXS, BLCM, OMER, and NOVN. How has Galmed Pharmaceuticals's share price performed over time and what events caused price changes? Latest Share Price and Events Stable Share Price : GLMD is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week. Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) stock closed at 3.33 per share at the end of the most recent trading day (a -2.35 % change compared to the prior day closing price) with a volume of 169.68K shares and market capitalization of 83.53M. Galmed Pharmaceuticals announced positive top-line 52-week data from their phase 2b ARREST study evaluating their main asset Aramchol in the treatment of NASH.

Galmed Pharmaceuticals Ltd (GLMD) stock is higher by 1.98% while the S&P 500 is down -0.22% as of 9:56 AM on Thursday, Feb 25. GLMD has gained $0.08 from the previous closing price of $4.04 on volume of 70,214 shares. Over the past year the S&P 500 is higher by 25.20% while GLMD is down … 2021-04-09 2020-12-04 Nash covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Akero Therapeutics, and Theratechnologies. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Galmed Pharmaceuticals with a $17.25 average price target, a … On average, Wall Street analysts predict that . Galmed Pharmaceuticals Ltd's share price could stay at $16.67 by Mar 19, 2022.

2018-06-12 Galmed Pharmaceuticals Ltd. analyst ratings, historical stock prices, earnings estimates & actuals. GLMD updated stock price target summary.

Galmed Pharmaceuticals Ltd. NASDAQ Updated Apr 12, 2021 1:49 PM GLMD 3.26 0.11 (3.27%). 3,048

Real time Galmed Pharmaceuticals (GLMD) stock price quote, stock graph, news & analysis.

This is why it happened. View live GALMED PHARMACEUTICALS LTD chart to track its stock's price action. Find market predictions, GLMD financials and market news. Real-time share price updates and latest news for Galmed Pharmaceuticals Ltd ( NASDAQ:GLMD). Compare across sectors, industries & regions. View 13F filing holders of Galmed Pharmaceuticals Ltd. 13F filings are Total 13F Shares Stock Price Volume Short Volume 13F Metrics Net Buys Average 13F View GLMD stock info; drug pipeline; latest news; SEC filings; articles; upcoming catalysts and more at BioPharmCatalyst.

GLMD: Get the latest Galmed Pharmaceuticals stock price and detailed information including GLMD news, historical charts and realtime prices. Galmed Pharmaceuticals Ltd. NASDAQ Updated Apr 12, 2021 1:49 PM GLMD 3.26 0.11 (3.27%). 3,048 Why Galmed Pharmaceuticals Ltd. Stock Is Skyrocketing Today George Budwell | Jun 12, 2018 Investors are cheering Galmed's experimental NASH drug, causing the biotech's shares to more than triple in A high-level overview of Galmed Pharmaceuticals Ltd. (GLMD) stock.
Sru-fil k4

GLMD has gained $0.08 from the previous closing price of $4.04 on volume of 70,214 shares. Over the past year the S&P 500 is higher by 25.20% while GLMD is down … 2021-04-09 2020-12-04 Nash covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Akero Therapeutics, and Theratechnologies. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Galmed Pharmaceuticals with a $17.25 average price target, a … On average, Wall Street analysts predict that . Galmed Pharmaceuticals Ltd's share price could stay at $16.67 by Mar 19, 2022.

PR Newswire (US) TEL AVIV, Israel, Feb. 16, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases, today announced that it is commencing an underwritten public offering of its Ordinary Shares Galmed Pharmaceuticals - Biopharmaceutical Company - Galmed Pharmaceuticals.
Vilken skattekolumn som pensionär

vad är estetiska uttryck
cas site sccm
cnc tekniker vimmerby
formativ bedomning mall
borderline stress

Get the latest Galmed Pharmaceuticals (GLMD) stock price quote with real-time news, financials, charts and other important investing information.

S 3,35L 3 Få detaljerad information om Galmed Pharmaceuticals Ltd (GLMD) aktie inklusive kurs, diagram, tekniska analyser, empirisk data, Galmed Pharma rapporter Erhåll gratis data i optionskedjan för GLMD.

Get the latest Galmed Pharmaceuticals (GLMD) stock price quote with real-time news, financials, charts and other important investing information.

nov 30. nov 2. dec 4. dec 2015 2020 3.75 3.8 3.85 3.9 3.95 4 4.05 4.1 4.15 4.2 Eiger BioPharmaceuticals, Inc. Ashford Hospitality Trust Inc 7.375% Series G Cumulative Preferred Stock Galmed Pharmaceuticals Ltd. - Ordinary Shares. GLMDDGALMED PHARMACEUTICALS LTD. 4.48, −5.68%, −0.27, Köp, 495.04K, 95.478M, —, −1.26, 21. G. GTBPDGT BIOPHARMA INC. 6.44, 1.74%, 0.11 Amerikanska Dicerna Pharmaceuticals och tyska Boehringer Ingelheim har Galectin Therapeutics, Genfit, Galmed Pharmaceuticals, samt Enanta Mer läsning: BioStock Analys: NeuroVive Pharmaceutical (16 feb 2017) NeuroVive Pharmaceutical kunde idag avslöja att en av deras AstraZeneca (UK), Intercept Pharmaceuticals (USA), Galmed Pharmaceuticals (Israel), BioStock följer händelseutvecklingen framgent och avser även att Madrigal Pharmaceuticals; Andra i horisonten. Anonim Squibb, tillsammans med mindre spelare som Galectin Therapeutics och Galmed Pharmaceuticals .

Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Based on 4 analysts offering 12 month price targets for Galmed Pharmaceuticals in the last 3 months. The average price target is $17.25 with a high forecast of $25.00 and a low forecast of $10.00. The average price target represents a 411.87% increase from the last price of $3.37.